59 filings
Page 2 of 3
8-K
j2po9ueeunc ws2737p9
14 Feb 23
Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life
7:18am
8-K
nr68747
25 Jan 23
Entry into a Material Definitive Agreement
4:49pm
8-K
q4a5q5cpv ot
23 Jan 23
Entry into a Material Definitive Agreement
6:31am
8-K
aep4w vr8omc
29 Dec 22
Disc Medicine Announces Completion of Merger with Gemini Therapeutics
5:21pm
8-K
w6vp9jdes
28 Dec 22
Submission of Matters to a Vote of Security Holders
1:20pm
8-K
y5jmb phc4510i
27 Dec 22
Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic Protoporphyria
8:05am
8-K
7iz71g8gv4 7da
13 Dec 22
Disc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting
9:06am
8-K
bx9v s3cw
8 Dec 22
Departure of Directors or Certain Officers
4:31pm
8-K
ye36ea5yy4
31 Oct 22
AURORA study designed to evaluate bitopertin as a potential disease-modifying treatment for adults with EPP in the United States
9:05am
8-K
dnvl2r5l
10 Aug 22
Conference Call Transcript
5:10pm
8-K
n2ys 63kkzlmhvjmu
10 Aug 22
Gemini Therapeutics and Disc Medicine Announce Merger Agreement
12:00am
8-K
koq6y40lsp7e5 vach2u
5 Apr 22
Departure of Directors or Certain Officers
8:00am
8-K
1ju6i 6iq8
10 Mar 22
Gemini Therapeutics Reports 2021 Financial Results
7:05am
8-K
s5omxm
28 Feb 22
Gemini Therapeutics Provides Corporate Update
8:35am
8-K
fd5835t99k k60
14 Jan 22
Departure of Directors or Certain Officers
8:00am
8-K
vso314e9ho 7htk9c
10 Jan 22
Gemini Therapeutics Provides GEM103 Program Update
8:05am
8-K
un0g9h
15 Nov 21
Gemini Therapeutics Reports Third Quarter 2021 Financial Results
7:35am
8-K
8g9uaan
12 Nov 21
Gemini Therapeutics Announces Poster Presentation at AAO 2021
8:35am
8-K
uqxqjz6qrdyk w20
6 Oct 21
Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic Atrophy
7:01am
8-K
uws98qm3wgi zpjxpl
1 Oct 21
Submission of Matters to a Vote of Security Holders
7:00am